Scandinavian ChemoTech: Comment on directed issue and updated valuation - Redeye

Redeye provides a short comment on the recently announced directed issue from Scandinavian ChemoTech. The company is raising cSEK5m at a premium to both the current share price and the 10-day VWAP. We are encouraged by the news, having previously modelled a small rights issue at a discount, and therefore raise our valuation slightly due to the lower-than-expected dilution.

Länk till analysen i sin helhet: https://www.redeye.se/research/1121052/scandinavian-chemotech-comment-on-directed-issue-and-updated-valuation?utm_source=finwire&utm_medium=RSS